StreetInsider.com News Articles

Senhwa's CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research

Wed, 12 Aug 2026 03:01:00 -0400

TAIPEI and SAN DIEGO, Aug. 12, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced a significant research advance involving its investigational drug Pidnarulex (CX-5461). A multinational research team comprising investigators from Poland, Slovakia, France and Senhwa Biosciences in Taiwan found that, under specific cell-based experimental conditions, controlled light activation increased the cancer-cell-killing activity of CX-5461 by up to 96-fold and induced immunogenic cell death (ICD). The findings, published in the peer-reviewed journal Nucleic Acids Research, reveal that

Senhwa's CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research

Wed, 12 Aug 2026 03:01:00 -0400

Senhwa's CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research

Wed, 12 Aug 2026 03:01:00 -0400

Senhwa's CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research

Wed, 12 Aug 2026 03:01:00 -0400

Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

Thu, 06 Aug 2026 05:14:00 -0400

TAIPEI, Aug. 6, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced that the Taiwan Food and Drug Administration (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor. The TFDA clearance follows clearance by the U.S. Food and Drug Administration (FDA) in June 2026, enabling the study to proceed in both Taiwan and the United States. This marks an important step in the

Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

Thu, 06 Aug 2026 05:14:00 -0400

Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

Thu, 06 Aug 2026 05:14:00 -0400

Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

Thu, 06 Aug 2026 05:14:00 -0400

Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

Thu, 06 Aug 2026 05:14:00 -0400

Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

Thu, 06 Aug 2026 05:14:00 -0400

Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

Thu, 06 Aug 2026 05:14:00 -0400

Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

Thu, 06 Aug 2026 05:14:00 -0400

Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

Thu, 06 Aug 2026 05:14:00 -0400

Senhwa's CX-5461 Reaches Immuno-Oncology Milestone as its First Multicenter Combination Trial with PD-1 Inhibitor Receives TFDA Clearance

Thu, 06 Aug 2026 05:14:00 -0400

GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million